In the Margins
In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.
Most Read
The Securities and Exchange Commission has been accused of "over-regulation" in recent years as it has proposed and finalized dozens of rules in a relatively short ...
It's the Summer Solstice, and that means that for most of us the sun is shining, temperatures are heating up, and longer days allow for pursuits ...
When former BlackRock executive Salim Ramji takes the helm next month at Vanguard, the asset management behemoth's board of directors also will install its first-ever independent ...
Former BNY Mellon executive Joseph Keenan spent time during the pandemic learning "all things blockchain," knowledge that has come in handy since he was tapped in ...